Cargando…
Pharmacophore Selection and Redesign of Non-nucleotide Inhibitors of Anthrax Edema Factor
Antibiotic treatment may fail to protect individuals, if not started early enough, after infection with Bacillus anthracis, due to the continuing activity of toxins that the bacterium produces. Stable and easily stored inhibitors of the edema factor toxin (EF), an adenylyl cyclase, could save lives...
Autores principales: | Schein, Catherine H., Chen, Deliang, Ma, Lili, Kanalas, John J., Gao, Jian, Jimenez, Maria Estrella, Sower, Laurie E., Walter, Mary A., Gilbertson, Scott R., Peterson, Johnny W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509708/ https://www.ncbi.nlm.nih.gov/pubmed/23202316 http://dx.doi.org/10.3390/toxins4111288 |
Ejemplares similares
-
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant
por: Kelly, Cassandra D, et al.
Publicado: (2007) -
Emergence of Anthrax Edema Toxin as a Master Manipulator of Macrophage and B Cell Functions
por: Gnade, Bryan T., et al.
Publicado: (2010) -
Severe bullous cutaneous anthrax with malignant edema
por: Tartar, Ayşe Sağmak, et al.
Publicado: (2021) -
Laboratory evolution of artificially expanded DNA gives redesignable aptamers that target the toxic form of anthrax protective antigen
por: Biondi, Elisa, et al.
Publicado: (2016) -
In vivo dynamics of active edema and lethal factors during anthrax
por: Rougeaux, Clémence, et al.
Publicado: (2016)